Phase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcoma.

ABSTRACT:

Purpose

Uterine carcinosarcoma (UCS) is a rare but aggressive tumor with high rates of recurrence and poor prognosis, and novel therapies are urgently needed. P53 mutations are identified in over 90% of cases, and other cell cycle alterations are commonly found indicating potential vulnerability to Wee1 kinase inhibition. The purpose of this study was to determine the activity and safety of adavosertib, a Wee1 inhibitor, in recurrent or persistent UCS.

Patients and methods

This was a phase II single-institution study of patients with persistent or recurrent UCS. Eligible patients had a confirmed TP53 alteration, RECIST measurable disease, and prior treatment with platinum based systemic therapy. Patients were treated with adavosertib at a starting dose of 300 mg orall

SUBMITTER: Cham S 

PROVIDER: S-EPMC12269869 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature